瑞舒伐他汀在冠心病合并高脂血症治疗中的应用及对血清hs-CRP MFG-E8和Klotho的影响  

Effect of rosuvastatin in treatment of heart disease complicated with hyperlipidemia and its effect on level of hs-CRP,MFG-E8 and Klotho

作　　者：周云[1,2] 吴弘[1] 张超 缪志静 施珊岚 

机构地区：[1]第二军医大学附属长海医院心内科,上海200433 [2]上海市宝山区中西医结合医院心内科,上海201999

出　　处：《西部医学》2017年第3期339-342,共4页Medical Journal of West China

基　　金：上海市自然科学基金(10ZR1431100)

摘　　要：目的研究瑞舒伐他汀在冠心病合并高脂血症治疗中的应用及对血清hs-CRP、MFG-E8及Klotho水平的影响。方法选取2015年7月~2016年6月本院收治的170例冠心病合并高脂血症患者,根据入院顺序分为试验组和对照组,每组85例。对照组采用常规治疗,观察组在此基础上服用瑞舒伐他汀。分析两组患者治疗前后血脂水平、血清超敏C反应蛋白(hs-CRP)、乳脂肪球表皮生长因子8(MFG-E8)和Klotho基因水平,比较两组患者的临床疗效。结果观察组总的临床有效率显著高于对照组[90.59%(77/85例)vs 77.65%(66/85例),P<0.05]。观察组的低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、总胆固醇(TC)水平显著低于对照组[(2.81±0.25)、(1.31±0.53)、(4.32±0.35)mmol/L vs(4.86±0.87)、(2.21±0.61)、(5.15±0.65)mmol/L,P<0.05],高密度脂蛋白胆固醇(HDL-C)水平显著高于对照组[(1.58±0.25)mmol/L vs(1.24±0.18)mmol/L,P<0.05]。观察组的hs-CRP水平显著低于对照组[(2.75±0.41)mg/ml vs(3.24±0.56)mg/ml,P<0.05],MFG-E8、Klotho水平显著高于对照组[(504.21±13.15)、(41.24±5.43)pg/ml vs(267.21±8.34)、(32.67±3.87)pg/ml(P<0.05)]。结论冠心病合并高脂血症患者应用瑞舒伐他汀进行治疗,可有效调节hs-CRP、MFG-E8及Klotho水平,临床疗效良好。Objective To study the effect of rosuvastatin in treatment of heart disease complicated with hyperlipidemia and its effect on level of hs-CRP, MFG-E8 and Klotho. Methods From July 2015 to June 2016, 170 patients with CHD complicated with hyperlipidemia were divided into experimental group and control group according to admission order, and 85 patients in each group. The control group was treated with routine therapy, and the observation group was taken rosuvastatin on this basis of control group. The levels of serum high sensitive C-reactive protein （hs-CRP）, milk fat globulin epidermal growth factor 8 （MFG-ES） and Klotho gene were measured before and after the treatment. The clinical efficacy was compared between the two groups. Results The total clinical efficacy of the observation group was significantly higher than that of the control group [90.59% （77/85） VS 77.65% （66/85）1 （P〈0.05）. The low density lipoprotein cholesterol （LI）L-C）, triglyeeride （TG）, total cholesterol （TC） and triglyeeride （TG） of experimental group were significantly higher than that of control group [（2.81±0.25） mmol/L, （1.31±0.53） retool/L, （4.32 ± 0.35） mmol/ L VS （4.86±0.87） mmol/L, （2.21±0.61） retool/L, （5.15±0.65） mmol/L]. The high density lipoprotein cholesterol （HDL-C） of experimental group was higher than that of control group. The level of hs-CRP in experimental group was significantly lower than those in the control group （P〈0.05）. MFG-E8 and Klotho levels of experimental group were significantly higher than those in the control group （P〈0.05）. Conclusion Treatment with rosuvastatin in patients with coronary heart disease and hyperlipidemia can effectively regulate the levels of hs-CRP, MFG-E8 and Klotho, and the clinical curative effect is good.

关 键 词：瑞舒伐他汀 冠心病 高脂血症 超敏C反应蛋白 乳脂肪球表皮生长因子8 KLOTHO基因 

分 类 号：R541.4[医药卫生—心血管疾病] R589.2[医药卫生—内科学]